CoChat

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis

Trapp, Elisabeth, Janni, Wolfgang, Schindlbeck, Christian, Jückstock, Julia, Andergassen, Ulrich, de Gregorio, Amelie, Alunni-Fabbroni, Marianna, Tzschaschel, Marie, Polasik, Arkadius, Koch, Julian G, Friedl, Thomas W P, Fasching, Peter A, Haeberle, Lothar, Fehm, Tanja, Schneeweiss, Andreas, Beckmann, Matthias W, Pantel, Klaus, Mueller, Volkmar, Rack, Brigitte, Scholz, Christoph, SUCCESS Study Group · 2019 · JNCI: Journal of the National Cancer Institute
Cited by 140

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The prognostic relevance of circulating tumor cells (CTCs) at the time of primary diagnosis has been well established. However, little information is available regarding their prognostic relevance to follow-up care. METHODS: The multicenter, open-label, phase III SUCCESS A trial compared two adjuvant chemotherapy regimens followed by 2 vs 5 years of zoledronate for early-stage, high-risk breast cancer patients. The presence of CTCs was assessed before and 2 years after chemotherapy using the FDA-approved CellSearch System. Overall survival (OS) and disease-free survival (DFS) were analyzed using univariate log-rank tests and multivariable Cox regressions. OS and DFS were measured starting from an assessment of CTCs 2 years after the completion of chemotherapy. All statistical tests were two-sided. RESULTS: The sample included 1087 patients who participated in the translational research program of the SUCCESS A trial and for whom sufficient translational data were available regarding CTC status at baseline and at the 2-year follow-up visit. Two years after chemotherapy, 198 (18.2%) patients were CTC-positive. The median follow-up after this timepoint was 37 months. Cox regressions that included CTC status at baseline revealed that CTC status 2 years after chemotherapy had statistically significant and independent prognostic relevance for OS (hazard ratio [HR] = 3.91, 95% confidence interval [CI] = 2.04 to 7.52, P < .001) and DFS (HR = 2.31, 95% CI = 1.50 to 3.55, P < .001). CONCLUSION: The presence of CTCs 2 years after chemotherapy was associated with decreased OS and DFS. Based on these results, active individualized surveillance strategies for breast cancer survivors based on biomarkers should be reconsidered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djy152

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 140

Metadata

Authors
Trapp, E., Janni, W., Schindlbeck, C., Jückstock, J., Andergassen, U., de Gregorio, A., Alunni-Fabbroni, M., Tzschaschel, M., Polasik, A., Koch, J. G., Friedl, T. W. P., Fasching, P. A., Haeberle, L., Fehm, T., Schneeweiss, A., Beckmann, M. W., Pantel, K., Mueller, V., Rack, B., Scholz, C., & SUCCESS Study Group
Venue
JNCI: Journal of the National Cancer Institute
Published
2018-10-11
Volume
111
Issue
4
Pages
380-387
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2897267414
Cited by
140
References
7
FWCI
3.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. https://app.cochat.ai/papers/10.1093/jnci/djy152
The paper
Trapp, E., Janni, W., Schindlbeck, C., Jückstock, J., Andergassen, U., de Gregorio, A., Alunni-Fabbroni, M., Tzschaschel, M., Polasik, A., Koch, J. G., Friedl, T. W. P., Fasching, P. A., Haeberle, L., Fehm, T., Schneeweiss, A., Beckmann, M. W., Pantel, K., Mueller, V., Rack, B., . . . SUCCESS Study Group. (2019). Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.